. Author manuscript; available in PMC: 2020 Jul 1.

Published in final edited form as: Clin Psychol Rev. 2019 May 3;71:27–38. doi: 10.1016/j.cpr.2019.05.001

Table B.1.

Studies Included in the Meta-Analyses

Study (Country)	N	Design	Sample	Mean Age (SD)	% Female	% Adv. Stage	Mean Time Since Dx (SD) in years	% Married	% Quality	Acceptance Measure [α]	General Distress Measure [α]	ES^a	Agg. ES^b
Acceptance of Cancer - General Distress:
Aarstad, Lode, Larsen, Bru, and Aarstad (2011) (Norway)	96	C-S	Head and Neck	61.00 (11.00)	21.88	-	4.00 (2.00)	-	67.86	COPE-A [.63]	BDI	−0.140	−0.140
Aguado Loi et al. (2013) (USA)	68	C-S	Breast	55.40 (10.40)	100.00	14.71	2.80 (1.50)	55.88	93.10	BCOPE-A	PHQ-9 [.91]	−0.320	−0.320
Asuzu and Elumelu (2013) (Nigeria)	237	C-S	Mixed	49.91 (13.48)	83.54	-	-	72.57	68.97	BCOPE-A	FACT-EWB	−0.065	−0.065
Avis et al. (2012) ^** (USA)	653	C-S	Breast	-	100.00	8.12	0.35 (0.10)	71.67	73.33	BCOPE-A	BDI	−0.280	−0.280
Baliousis, Rennoldson, Dawson, Mills, and das Nair (2017) ^** (UK)	45	Long.	Stem Cell	59.50 (11.70)	31.11	-	2.40 (3.47)	75.56	89.66	BCOPE-A	DASS-Dep	−0.221	−0.111
											DASS-Dis	−0.004
											DASS-A	−0.047
Bonnaud-Antignac, Bourdon, Dréno, and Quéreux (2017) (France)	78	Long.	Melanoma	53.26 (12.70)	42.31	0.00	1.92	70.51	61.29	BCOPE-A	QLQ-C30 EWB	−0.040^*	−0.040
Bossema et al. (2011) Sample 1 (Netherlands)	62	C-C	Rectal	68.60 (9.60)	25.81	-	-	-	63.33	ICQ-A [.85]	HADS-A [.75]	−0.390	−0.425
											HADS-D [.63]	−0.337
											QLQ-C30 EWB [.82]	−0.315^*
Bossema et al. (2011) Sample 2 (Netherlands)	60	C-C	Rectal	67.90 (10.30)	36.67	-	-	-	63.33	ICQ-A [.85]	HADS-A [.75]	−0.540	−0.671
											HADS-D [.63]	−0.551
											QLQ-C30 EWB [.82]	−0.551^*
Boyle, Stanton, Ganz, and Bower (2017) (USA)	175	Long.	Breast	53.00 (8.02)	100.00	9.71	1.43 (0.22)	78.20	83.33	BCOPE-A	PANAS-P [.93]	−0.074^*	−0.056
Boyle, Stanton, Ganz, and Bower (2017) (USA)	175	Long.	Breast	53.00 (8.02)	100.00	9.71	1.43 (0.22)	78.20	83.33	BCOPE-A	PANAS-N [.88]	−0.023	−0.056
Bright and Stanton (2018) (USA)	130	Long.	Breast	54.20 (11.70)	100.00	8.46	0.50 (0.21)	66.15	81.25	COPE-A [.62]	CES-D-NA [.84]	−0.150	−0.149
											CES-D-PA [.73]	−0.190^*
											CES-D-SOM [.75]	−0.120
											CES-D-INT [.49]	−0.010
Brunault et al. (2016) (France)	120	C-S	Breast	56.98 (10.80)	100.00	5.83	0.54	69.17	86.67	BCOPE-A	QLQ-C30 EWB	−0.530	−0.530
Bussell and Naus (2010) (USA)	59	Long.	Breast	50.00	100.00	30.50	-	-	68.75	BCOPE-A	BDI [.80]	−0.160	−0.245
											BAI [.86]	−0.106
											PSS [.86]	−0.229
											POMS [.94]	−0.281
Cameron (1999)¹ Sample 1 (USA)	25	Long.	Colorectal	63.00 (12.30)	100.00	24.00	1.62 (0.69)	68.00	83.33	COPE-A [.50]	POMS [.96]	0.200	0.200
Cameron (1999)¹ Sample 2 (USA)	19	Long.	Colorectal	69.10 (10.60)	0.00	36.90	1.72 (1.20)	57.90	83.33	COPE-A [.50]	POMS [.96]	0.250	0.250
Carver et al. (1993) (USA)	59	Long.	Breast	58.02 (10.83)	100.00	0.00	-	71.19	70.97	COPE-A [.68]	POMS [.87]	−0.680	−0.680
Chabowski et al. (2017) (Poland)	155	C-S	Lung	62.23 (9.86)	48.40	29.68	-	-	64.29	AIS	SF-8 MH	−0.747^*	−0.747
Chirico, Lucidi, Mallia, D’Aiuto, and Merluzzi (2015) (Italy)	123	C-S	Breast	45.69 (10.01)	100.00	23.60	-	-	67.86	CBI-2-A [.78]	STAI-S [.87]	−0.330	−0.370
	123	C-S	Breast	45.69 (10.01)	100.00	23.60	-	-	67.86	CBI-2-A [.78]	CES-D [.88]	−0.310	−0.370
Cieślak and Golusiński (2017) Sample 1 (Poland)	71	C-S	Breast	-	100.00	-	-	-	57.14	AIS	CWLA-D	−0.475	−0.475
Cieślak and Golusiński (2017) Sample 2 (Poland)	19	C-S	Breast	-	100.00	-	-	-	57.14	AIS	CWLA-D	−0.178	−0.178
Culver, Arena, Antoni, and Carver (2002) (USA)	131	Long.	Breast	54.82 (10.77)	100.00	0.00	-	55.73	70.97	BCOPE-A	DI [.77]	−0.230	−0.230
Dasch et al. (2010) (USA)	53	Long.	Breast	53.34 (9.99)	100.00	6.00	-	88.68	71.88	BCOPE-A [.67]	HADS-A [.87]	−0.170	−0.170
David, Montgomery, and Bovbjerg (2006) (USA)	60	Long.	Breast	52.00 (12.21)	100.00	-	-	55.00	66.67	BCOPE-A	POMS	−0.140	−0.140
De Feudis, Lanciano, and Rinaldi (2015) (Italy)	61	C-S	Breast	54.02 (11.92)	100.00	-	-	75.41	71.43	BCOPE-A [.57]	HADS-A [.81]	−0.320	−0.364
De Feudis, Lanciano, and Rinaldi (2015) (Italy)	61	C-S	Breast	54.02 (11.92)	100.00	-	-	75.41	71.43	BCOPE-A [.57]	HADS-D [.65]	−0.310	−0.364
Durá-Ferrandis et al. (2017) (USA) ^**	1,280	Long.	Breast	72.70 (5.90)	100.00	-	-	55.31	81.25	BCOPE-A [.67]	QLQ-C30 EWB [.75]	−0.047	−0.068
Durá-Ferrandis et al. (2017) (USA) ^**	1,280	Long.	Breast	72.70 (5.90)	100.00	-	-	55.31	81.25	BCOPE-A [.67]	SF-12 MH [.87]	−0.071	−0.068
Elsheshtawy, Abo-Elez, Ashour, Farouk, and El Zaafarany (2014) (Egypt)	56	C-S	Breast	52.00 (13.30)	100.00	12.50	-	62.50	57.14	BCOPE-A	HADS-A	−0.193	−0.259
	56	C-S	Breast	52.00 (13.30)	100.00	12.50	-	62.50	57.14	BCOPE-A	HADS-D	−0.255	−0.259
Fischbeck et al. (2015) ^** (Germany)	689	C-S	Melanoma	-	51.38	-	8.46	82.73	73.33	BCOPE-A	PHQ-9 [.86]	0.063	0.016
											GAD-7 [.89]	0.062
											QLQ-C30 EWB [.89]	−0.085^*
Fischer et al. (2013) ^** (Netherands)	57	Inter.	Breast	50.70 (6.90)	100.00	-	-	85.96	78.13	BCOPE-A [.70]	HSCL-25 [.90]	−0.353	−0.353
Gillanders, Sinclair, MacLean, and Jardine (2015) (Scotland)	105	C-S	Mixed	-	45.71	-	3.59 (4.61)	76.19	93.10	BCOPE-A	HADS-A [.89]	0.036	−0.005
											HADS-D [.83]	0.109
											FACT-EWB	−0.158
Green, Pakenham, Headley, and Gardiner (2002) ^** (Australia)	56	Inter.	Prostate	73.30 (6.40)	0.00	-	-	-	87.50	COPE-A	DASS [.92]	0.373	0.373
Hagan et al. (2017) (USA)	350	C-S	Mixed	64.86 (10.86)	46.00	-	-	70.00	71.43	BCOPE-A [.81]	HADS-A	−0.289	−0.410
Hagan et al. (2017) (USA)	350	C-S	Mixed	64.86 (10.86)	46.00	-	-	70.00	71.43	BCOPE-A [.81]	HADS-D	−0.368	−0.410
Hamilton et al. (2014) ^** (USA)	351	Long.	Hematologic Malignancy	49.01	47.86	-	1.52 (2.35)	-	75.00	BCOPE-A	FACT-EWB	−0.323^*	−0.244
											POMS-D	−0.274
											POMS-A	−0.196
											POMS-T	−0.140
											POMS-C	−0.172
											POMS-F	−0.013
Heitzmann et al. (2011) ^** (USA)	31	C-S	Mixed	-	-	-	-	-	67.86	CBI-A	FACT-EWB	−0.710^*	−0.710
Hoyt, Gamarel, Saigal, and Stanton (2016) ^** (USA)	171	Long.	Testicular	25.00 (3.30)	0.00	-	2.46 (1.48)	44.00	75.00	BCOPE-A	FACT-EWB	−0.330^*	−0.330
Hsu and Wang (2014)² ^** (Taiwan)	311	Long.	Breast	47.54 (8.79)	100.00	-	-	89.40	-	BCOPE-A	HADS-A	−0.060	−0.150
Hsu and Wang (2014)² ^** (Taiwan)	311	Long.	Breast	47.54 (8.79)	100.00	-	-	89.40	-	BCOPE-A	HADS-D	−0.200	−0.150
Ichikura, Yamashita, Sugimoto, Kishimoto, and Matsushima (2018) ^** (Japan)	116	C-S	Head and Neck	-	9.48	-	-	-	85.71	BCOPE-A [.68]	BDI [.88]	−0.017	−0.017
Karademas, Tsagaraki, and Lambrou (2009) ^** (Greece)	40	C-S	Mixed	-	-	-	-	-	64.29	AIS [.80]	GHQ [.92]	−0.430	−0.430
Keeling, Bambrough, and Simpson (2013) (UK)	74	C-S	Brain	38.30 (10.67)	52.70	0.00	2.13 (1.52)	-	76.67	BCOPE-A [.75]	HADS-A [.88]	−0.310	−0.347
											HADS-D [.79]	−0.210
											PANAS-P [.95]	−0.330^*
Kulpa, Ziętalewicz, Kosowicz, Stypuła-Ciuba, and Ziółkowska (2016) (Poland)	78	C-S	Gynecological	54.00	100.00	-	-	-	64.29	CERQ-A [.72]	HADS-A	−0.297	−0.398
	78	C-S	Gynecological	54.00	100.00	-	-	-	64.29	CERQ-A [.72]	HADS-D [.75]	−0.393	−0.398
Lambert et al. (2016) ^** (Australia)	42	Inter.	Prostate	63.76 (6.75)	0.00	-	-	100.00	80.65	BCOPE-A	HADS-A	0.200	0.161
Lambert et al. (2016) ^** (Australia)	42	Inter.	Prostate	63.76 (6.75)	0.00	-	-	100.00	80.65	BCOPE-A	HADS-D	0.078	0.161
Li et al. (2015) (China)	665	C-C	Breast	45.55 (6.43)	100.00	0.00	0.01 (0.02)	94.10	87.10	CERQ-A	FACT-EWB	−0.550^*	−0.550
Low, Stanton, Thompson, Kwan, and Ganz (2006) (USA)	417	Long.	Breast	58.10	100.00	-	-	69.00	65.52	BCOPE-A [.74]	CES-D [.70]	−0.250	−0.250
Lyons et al. (2015) ^** (USA)	31	Inter.	Breast	48.90 (6.52)	100.00	22.58	-	87.10	63.33	BCOPE-A	HADS-A	0.140	0.184
											HADS-D	0.510
											FACT-EWB	−0.200^*
Manne, Ostroff, and Winkel (2007) (USA)	238	Inter.	Breast	49,50 (10.40)	100.00	12.00	-	-	84.38	COPE-A [.74]	MHI-A [.84]	−0.270	−0.351
											MHI-D [.87]	−0.240
											MHI-L [.80]	−0.290
											MHI-WB [.87]	−0.310^*
Mazanec, Daly, Douglas, and Musil (2011) ^** (USA)	80	Long.	Mixed	62.28 (12.92)	58.75	12.5	-	63.75	76.67	CBI-A	PAIS	−0.591	−0.591
Merluzzi and Martinez Sanchez (1997) (USA)	124	C-S	Mixed	60.50	66.00	36.00	-	70.00	60.71	CBI-A [.87]	MHI	−0.320^*	−0.320
Merluzzi and Martinez Sanchez (2018) (USA) ^**	72	C-S	Breast	55.00	100.00	32.40	3.01	100.00	72.41	CBI-A	MHI [.91]	−0.350^*	−0.330
Merluzzi and Martinez Sanchez (2018) (USA) ^**	72	C-S	Breast	55.00	100.00	32.40	3.01	100.00	72.41	CBI-A	PAIS [.97]	−0.221^*	−0.330
Merluzzi, Philip, Yang, Heitzmann, and Conley (2015) ^** (USA)	471	C-S	Mixed	-	-	-	-	-	64.29	BCOPE-A	FACT-EWB	−0.196^*	−0.440
											HADS-A	−0.128
											HADS-D	−0.177
										CBI-A	FACT-EWB	−0.559^*
											HADS-A	−0.450
											HADS-D	−0.504
Merluzzi et al. (2018) Sample 1 (USA)	560	C-S	Mixed	63.10	66.61	-	-	60.54	67.86	CBI-3-A [.81]	CES-D	−0.590	−0.590
Merluzzi et al. (2018) Sample 2 (USA)	151	C-S	Mixed	63.00	62.91	-	-	66.89	67.86	CBI-3-A [.81]	HADS-A	−0.422	−0.553
Merluzzi et al. (2018) Sample 2 (USA)	151	C-S	Mixed	63.00	62.91	-	-	66.89	67.86	CBI-3-A [.81]	HADS-D	−0.535	−0.553
Merluzzi et al. (2018) Sample 3 (USA)	287	C-S	Mixed	64.10	64.46	-	-	60.28	67.86	CBI-3-A [.81]	CES-D	−0.296	−0.296
Milbury et al. (2016)² ^** (USA)	158	C-S	Lung	62.90 (10.10)	37.30	69.20	0.18 (0.13)	97.60	-	COPE-A	BSI	−0.094	−0.094
Mosher, Duhamel, Egert, and Smith (2010) ^** (USA)	87	C-S	Breast	50.00 (10.00)	100.00	49.00	3.00 (4.00)	50.57	85.71	CBI-A [.57]	MHI [.93]	−0.536^*	−0.536
Nairn and Merluzzi (2003) ^** Sample 1 (USA)	137	C-S	Mixed	-	-	-	-	-	64.29	CBI-A	PAIS	−0.566	−0.566
Nairn and Merluzzi (2003) ^** Sample 2 (USA)	383	C-S	Mixed	-	-	-	-	-	64.29	CBI-A	FACT-EWB	−0.190^*	−0.252
Nairn and Merluzzi (2003) ^** Sample 2 (USA)	383	C-S	Mixed	-	-	-	-	-	64.29	CBI-A	CES-D	−0.247	−0.252
Northouse et al. (2013) ^** (USA)	484	Inter.	Mixed	60.50 (10.90)	61.40	-	3.62	-	83.87	BCOPE-A	FACT-EWB	−0.163^*	−0.163
Perczek (1999)¹ (USA)	31	Long.	Prostate	-	-	0.00	0.04	-	63.33	BCOPE-A	POMS [.93]	−0.150	−0.150
Peters, Goedendorp, Verhagen, van der Graaf, and Bleijenberg (2014) ^** (Netherlands)	137	C-S	Mixed	59.00	61.31	-	-	81.02	75.00	ICQ-A	HADS-A	−0.599	−0.597
	137	C-S	Mixed	59.00	61.31	-	-	81.02	75.00	ICQ-A	HADS-D	−0.435	−0.597
Polanski, Chabowski, Jankowska-Polanska, Janczak, and Rosinczuk (2018) Sample 1 (Poland)	72	C-S	Lung	62.80 (9.60)	43.06	51.39	-	62.50	65.52	AIS	QLQ-C30 EWB	−0.593	−0.593
Polanski et al. (2018) Sample 2 (Poland)	185	C-S	Lung	64.10 (8.80)	45.41	34.59	-	58.92	65.52	AIS	QLQ-C30 EWB	−0.742	−0.742
Pucheu et al. (2010)² ^** (France)	64	Long.	Mixed	55.40 (10.40)	75.00	-	0.23	-	-	ICQ-A	QLQ-C30 EWB	−0.230^*	−0.230
Rees-McGee (1991)¹ (USA)	101	C-S	Mixed	67.00 (8.30)	45.54	0.00	0.31 (0.10)	86.00	78.57	COPE-A [.84]	MHI [.94]	−0.560^*	−0.560
Reid-Arndt and Cox (2012) (USA) ^**	36	C-S	Breast	55.81 (10.45)	100.00	8.00	-	66.67	73.33	BCOPE-A	POMS-A	−0.382	−0.427
											POMS-D	−0.554
											POMS-F	−0.342
											POMS-V	−0.051
											POMS-T	−0.323
Roussi, Krikeli, Hatzidimitriou, and Koutri (2007) (Greece)	72	Long.	Breast	54.13	100.00	-	-	83.00	65.63	COPE-A	POMS	−0.430	−0.430
Schlegel, Talley, Molix, and Bettencourt (2009) (USA)	223	Long.	Breast	59.19 (12.72)	100.00	16.59	-	72.65	70.97	BCOPE-A	CES-D [.87]	−0.110	−0.110
Schnoll, Knowles, and Harlow (2002) ^** (USA)	109	C-S	Mixed	60.30 (11.00)	76.00	-	4.69 (5.28)	71.00	71.43	COPE-A	PAIS [.86]	−0.102	−0.102
Shino (2010)¹ Sample 1 (Namibia)	102	C-S	Mixed	56.77 (14.27)	100.00	-	0.97 (0.97)	31.37	74.07	CBI-A [.65]	WHO-P	−0.280	−0.348
											DT	−0.260
											HADS-A	−0.230
											HADS-D	−0.330
Shino (2010)¹ Sample 2 (South Africa)	125	C-S	Mixed	52.21 (12.56)	100.00	-	2.43 (2.52)	35.20	74.07	CBI-A [.91]	WHO-P	−0.530	−0.724
											DT	−0.460
											HADS-A	−0.640
											HADS-D	−0.660
Siwik et al. (2016)² ^** (USA)	45	C-S	Gynecological	55.16 (1284)	100.00	-	1.77	-	-	COPE-A	BDI	−0.160	−0.160
Solberg Nes, Ehlers, Patten, and Gastineau (2013) ^** (USA)	314	C-S	Hematologic Malignancy	58.00	37.00	-	-	-	64.29	BCOPE-A	STAI-T	−0.033	−0.136
											STAI-S	−0.071
											FACT-EWB	−0.299^*
											BDI [.92]	−0.027
Solberg Nes, Ehlers, Patten, and Gastineau (2014) ^** (USA)	213	Long.	Hematologic Malignancy	57.00 (12.03)	48.36	-	-	81.20	64.52	BCOPE-A	STAI-T	−0.021	−0.278
											STAI-S	−0.093
											FACT-EWB	−0.316^*
											BDI [.92]	−0.260
Soliday, Garofalo, Smith, Prostko, and Warner (2004) ^** (USA)	226	C-S	Mixed	52.40 (9.30)	72.12	71.00	-	81.00	65.52	BCOPE-A [.57]	HADS-A [.85]	0.040	0.087
	226	C-S	Mixed	52.40 (9.30)	72.12	71.00	-	81.00	65.52	BCOPE-A [.57]	HADS-D [.79]	0.110	0.087
Stanton, Danoff-Burg, and Huggins (2002) (USA)	70	Long.	Breast	52.63 (11.94)	100.00	0.00	-	70.00	80.65	COPE-A [.69]	POMS [.90]	0.030	0.030
Thornton (2000)¹ (USA)	106	Long.	Prostate	61.16 (7.22)	0.00	18.00	-	100.00	80.00	BCOPE-A	FACT-EWB [.76]	−0.190^*	−0.202
											PANAS-P	−0.300^*
											PANAS-N	−0.040
											PSS	−0.110
Thuné-Boyle, Stygall, Keshtgar, Davidson, and Newman (2013) (UK)	155	C-S	Breast	55.70 (13.50)	100.00	8.00	-	50.97	80.00	BCOPE-A [.65]	HADS-A [.85]	−0.251	−0.288
	155	C-S	Breast	55.70 (13.50)	100.00	8.00	-	50.97	80.00	BCOPE-A [.65]	HADS-D [.79]	−0.247	−0.288
Trevino, Fasciano, and Prigerson (2013) ^** (USA)	95	C-S	Mixed	33.40 (5.51)	68.42	52.63	3.40 (2.99)	56.84	72.41	PEACE-A [.74]	MQOL-PWB [.86]	−0.474^*	−0.474
Trevino et al. (2012) ^** (USA)	53	C-S	Mixed	33.89 (5.70)	66.04	52.83	3.72 (3.05)	49.06	82.76	BCOPE-A [.80]	MQOL-D [.90]	−0.109	−0.124
Trevino et al. (2012) ^** (USA)	53	C-S	Mixed	33.89 (5.70)	66.04	52.83	3.72 (3.05)	49.06	82.76	BCOPE-A [.80]	MQOL-A [.70]	−0.105	−0.124
Urcuyo, Boyers, Carver, and Antoni (2005) ^** (USA)	230	C-S	Breast	53.45 (12.34)	100.00	0.00	-	70.87	75.00	BCOPE-A	CES-D [.92]	−0.300	−0.341
Urcuyo, Boyers, Carver, and Antoni (2005) ^** (USA)	230	C-S	Breast	53.45 (12.34)	100.00	0.00	-	70.87	75.00	BCOPE-A	DI [.89]	−0.290	−0.341
Wagner, Johns, Brown, Hanna, and Bigatti (2016) ^** (USA)	12	Inter.	Mixed	59.10	66.67	90.91	-	100.00	80.65	S-PEACE	HADS-A	−0.569	−0.637
Wagner, Johns, Brown, Hanna, and Bigatti (2016) ^** (USA)	12	Inter.	Mixed	59.10	66.67	90.91	-	100.00	80.65	S-PEACE	HADS-D	−0.534	−0.637
Wang et al. (2018) (Taiwan)	180	C-S	Breast	49.33 (8.11)	100.00	18.40	-	87.80	75.00	BCOPE-A	HADS-A [.81]	−0.090	−0.250
											HADS-D [.76]	−0.350
											SF-36-MCS [.88]	−0.060^*
											BABS-P [.73]	−0.330^*
											BABS-N [.63]	−0.140
Warchala, Wojtyna, and Krysta (2015) ^** (Poland)	60	Long.	Leukemia	39.62 (12.80)	43.33	-	-	68.33	61.29	AIS [.82]	HADS-A [.79]	−0.159	−0.099
											HADS-D [.83]	−0.057
											RSC-P [.83]	−0.264^*
Yang, Brothers, and Andersen (2008) ^** (USA)	65	Long.	Breast	54.00 (11.00)	100.00	100.00	-	72.00	80.65	BCOPE-A	SF-36-MCS [.86]	−0.487^*	−0.487
Yeung, Lu, and Lin (2014) (China)	238	C-S	Mixed	55.70 (9.10)	74.37	17.65	-	90.34	79.31	CBI-A [.84]	QOL-CS PWB [.90]	−0.500^*	−0.500
Yu and Sherman (2015) ^** (Australia)	338	C-S	Breast	53.50 (9.22)	100.00	28.70	2.76 (1.86)	100.00	75.86	BCOPE-A [.67]	DASS-Dep [.88]	−0.250	−0.274
											DASS-Dis [.89]	−0.230
											DASS-A [.81]	−0.190
Acceptance of Cancer - Cancer-Specific Distress:
Boyle et al. (2017) ^** (USA)	175	Long.	Breast	53.00 (8.02)	100.00	9.71	1.43 (0.22)	78.29	83.33	BCOPE-A	IOC-W [.94]	−0.045	−0.045
Hoyt et al. (2014) ^** (USA)	66	C-S	Prostate	65.76 (9.04)	0.00	-	-	89.40	64.52	BCOPE-A	IES-I	−0.090	−0.090
Langford et al. (2017) ^** (USA)	957	C-S	Mixed	57.47 (11.87)	78.89	67.92	-	64.68	83.33	BCOPE-A [.68]	IES [.92]	−0.171	−0.171
Lebel et al. (2014) ^** (Canada)	56	Inter.	Mixed	54.80 (9.00)	100.00	32.20	-	58.90	93.10	BCOPE-A [.81]	FORS [.83]	−0.224	−0.279
Lebel et al. (2014) ^** (Canada)	56	Inter.	Mixed	54.80 (9.00)	100.00	32.20	-	58.90	93.10	BCOPE-A [.81]	IES [.79]	−0.260	−0.279
Low et al. (2006) (USA)	417	Long.	Breast	58.10	100.00	-	-	69.00	65.52	BCOPE-A [.74]	IES-R-C [.89]	−0.190	−0.190
Manne et al. (2007) (USA)	238	Inter.	Breast	49,50 (10.40)	100.00	12.00	-	-	84.38	COPE-A [.74]	IES [.89]	−0.260	−0.260
Reid-Arndt and Cox (2012) ^**	36	C-S	Breast	55.81 (10.45)	100.00	8.00	-	66.67	73.33	BCOPE-A	IES-R-C	−0.398	−0.398
Solberg Nes et al. (2013) ^** (USA)	314	C-S	Hematologic Malignancy	58.00	37.00	-	-	-	64.29	BCOPE-A	IES [.92]	−0.182	−0.182
Solberg Nes et al. (2014) ^** (USA)	213	Long.	Hematologic Malignancy	57.00 (12.03)	48.36	-	-	81.20	64.52	BCOPE-A	IES [.92]	−0.254	−0.254
Stanton et al. (2002) (USA)	70	Long.	Breast	52.63 (11.94)	100.00	0.00	-	70.00	80.65	COPE-A [.69]	FORS [.76]	−0.070	−0.070
Thornton (2000)¹ (USA)	106	Long.	Prostate	61.16 (7.22)	0.00	18.00	-	100.00	80.00	BCOPE-A	IES-I [.79]	−0.040	−0.075
Thornton (2000)¹ (USA)	106	Long.	Prostate	61.16 (7.22)	0.00	18.00	-	100.00	80.00	BCOPE-A	IES-A [.82]	−0.090	−0.075
Urcuyo et al. (2005) ^** (USA)	230	C-S	Breast	53.45 (12.34)	100.00	0.00	-	70.87	75.00	BCOPE-A	PCBC-L	−0.130	−0.133
Urcuyo et al. (2005) ^** (USA)	230	C-S	Breast	53.45 (12.34)	100.00	0.00	-	70.87	75.00	BCOPE-A	PCBC-R	−0.100	−0.133
Yang et al. (2008) ^** (USA)	65	Long.	Breast	54.00 (11.00)	100.00	100.00	-	72.00	80.65	BCOPE-A	IES-C [.89]	−0.296	−0.296

Pearson’s r.

The aggregated effect sizes.

Denotes doctoral dissertation

Denotes conference presentation

Denotes ES that was reverse-coded.

^**

Denotes a record that included additional information from the author.

Note. N = Sample size for the effect size reported; α = Cronbach’s alpha for the measure; ES = Effect size; Adv. stage = Advanced-stage cancer (e.g., stage III or IV); Mean Time Since Dx = Mean time since cancer diagnosis (in years); SD = Standard Deviation; Study Designs are listed as C-C= Case-control, C-S= Cross-Sectional, Inter.= Intervention, and Long.= Longitudinal; Quality = Study reporting quality as measured by the Strengthening the reporting of observational studies in epidemiology [STROBE Checklist] (von Elm, Altman, & Egger, 2008). Acceptance of Cancer Measures: AIS = Acceptance of Illness Scale; BCOPE-A = Brief COPE - Acceptance Subscale; CBI-A = Cancer Behavior Inventory - Accepting Cancer/Maintaining Positive Attitude Subscale; CBI-2-A = Cancer Behavior Inventory version 2.0 - Accepting Cancer/Maintaining Positive Attitude Subscale; CBI-3-A = Cancer Behavior Inventory version 3.0 - Accepting Cancer/Maintaining Positive Attitude Subscale; CCCS-A = Coping with Colorectal Cancer Scale - Acceptance Subscale; CERQ-A = Cognitive Emotion Regulation Questionnaire - Acceptance Subscale; COPE-A = COPE Acceptance Subscale; ICQ-A = Illness Cognitions Questionnaire - Acceptance Subscale; PEACE-A = Peace, Equanimity and Acceptance in the Cancer Experience - Acceptance Subscale; S-PEACE = Single item peaceful acceptance of cancer. General Distress Measures: BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; BSI-A = Brief Symptom Inventory- Anxiety Subscale; CES-D = Center for Epidemiologic Studies Depression Scale; CES-D-INT = Center for Epidemiologic Studies Depression Scale - Interpersonal Subscale; CES-D-NA = Center for Epidemiologic Studies Depression Scale - Negative Affect Subscale; CES-D-PA = Center for Epidemiologic Studies Depression Scale - Positive Affect Subscale; CES-D-SOM = Center for Epidemiologic Studies Depression Scale - Somaticizing Subscale; BSI-D = Brief Symptom Inventory - Depression Subscale; BSI-GSI = Brief Symptom Inventory - Global Severity Index; CWLA-D = Coping with Loss of Ability Scale - Depression Subscale; DASS = Depression Anxiety Distress Scales-21 Total Score; DASS-A = Depression Anxiety Distress Scales-21 - Anxiety Subscale; DASS-Dep = Depression Anxiety Distress Scales-21 - Depression Subscale; DASS-Dis = Depression Anxiety Distress Scales-21 - Distress Subscale; DI = Distress Index; DS = Demoralization Scale; DT = Distress Thermometer; FACT-EWB = Functional Assessment of Cancer Therapy - Emotional Well-being Subscale; GAD-7 = Generalized Anxiety Disorder-7; GHQ = General Health Questionnaire; HADS = Hospital Anxiety and Depression Scale - Total Score; HADS-A = Hospital Anxiety and Depression Scale - Anxiety Subscale; HADS-D = Hospital Anxiety and Depression Scale - Depression Subscale; HSCL-25 = Hopkins Symptom Checklist 25; MHI = Mental Health Inventory; MHI-A = Mental Health Inventory-Anxiety Subscale; MHI-D = Mental Health Inventory-Depression Subscale; MHI-L = Mental Health Inventory - Loss of Behavioral and Emotional Control Subscale; MHI-WB = Mental Health Inventory - Well-being Subscale; MQOL-A = McGill Quality of Life Questionnaire - Anxiety Subscale; MQOL-D = McGill Quality of Life Questionnaire - Depression Subscale; MQOL-PWB = McGill Quality of Life Questionnaire - Psychological Quality of Life Subscale; PAIS = Psychological Adjustment to Physical Illness Scale: Psychological Distress Subscale; PANAS = Positive and Negative Affect Schedule - Negative Affect; PANAS = Positive and Negative Affect Schedule - Positive Affect; PHQ-8 = Patient Health Questionnaire-8; PHQ-9 = Patient Health Questionnaire-9; POMS = Profile of Mood States: Total Mood Disturbance; POMS-A = Profile of Mood States - Anger Subscale; POMS-C = Profile of Mood States - Confusion Subscale; POMS-D = Profile of Mood States - Depression Subscale; POMS-F = Profile of Mood States - Fatigue Subscale; POMS-T = Profile of Mood States - Tension Subscale; PROMIS-A = Patient-Reported Outcomes Measurement Information System - Anxiety Scale; PROMIS-D = Patient-Reported Outcomes Measurement Information System - Depression Scale; PSS = Perceived Stress Scale; QLQ-C30 EWB = EORTC Quality of Life Questionnaire - Emotional Well-being Subscale; QOL-CS PWB = Quality of Life-Cancer Survivors Instrument - Psychological Well-being Subscale; SCL-90 = Symptom Distress Checklist-90 - Global Severity Index; SF-12-MCS = Short Form 12 - Mental Component Score; SF-36-MCS = Short Form 36 - Mental Component Score; STAI-S = State-Trait Anxiety Inventory - State Anxiety Subscale; STAI-T = State-Trait Anxiety Inventory - Trait Anxiety Subscale; ZDS = Zung’s Depression Scale; WHO-P = World Health Organization Quality of Life Instrument - Psychological Health Subscale. Cancer-Specific Distress Measures: IES-A = Impact of Events Scale - Avoidance Subscale; IES-C = Impact of Events Scale - Combined Score; IES-I = Impact of Events Scale - Intrusions Subscale; IES-R-A = Impact of Events Scale Revised - Avoidance Subscale; IES-R-C = Impact of Events Scale Revised - Combined Score; IES-R-H = Impact of Events Scale Revised – Hyperarousal Subscale; IES-R-I = Impact of Events Scale Revised - Intrusions Subscale; IOC-W = Impact of Cancer Scale - Worry Subscale; FORS = Fear of Recurrence Scale; PCBC-L = Profile of Concerns About Breast Cancer - Life and Pain Issues Subscale; PCBC-R = Profile of Concerns About Breast Cancer - Rejection Issues Subscale; PCL-C = PTSD Checklist: Civilian Version.